Yes, plenty of people with a different view and just to be clear this is not a cure by any stretch of the imagination. But what is clear if the FDA knocks this back it will be through gritted teeth, they want a AD drug approved and seem to want this one approved. Just with respect to the FDA wanting a product on the market the recent Lilly AD/PD call suggest that that company has had many discussions with the FDA and they were still commenting on the possibility that donanemab might be approved on just the TB1 trial and an early look at data from the larger TB2 trial. The FDA wants treatment options in the market.
CGS Price at posting:
92.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)